OmniActive Health Technologies Acquires ENovate Biolife to Expand Portfolio of Clinically Proven Health Ingredients

OmniActive Health Technologies (OmniActive) announced the acquisition of ENovate Biolife (ENovate), further strengthening its commitment to innovative...

November 05, 2024 | Tuesday | News
QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Cleared by FDA for Clinical Use

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...

November 04, 2024 | Monday | News
Novo Nordisk's SELECT Trial Reveals Semaglutide 2.4 mg Reduces Hospital Admissions for Patients with Obesity and Cardiovascular Disease

Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.4 mg significantly ...

November 04, 2024 | Monday | News
American Lung Association Launches Free Lung Cancer Screenings for Illinois Residents in Honor of Lung Cancer Awareness Month

November is Lung Cancer Awareness Month, and the American Lung Association (Lung Association) is kicking it off by offering free lung cancer screenings to&...

November 01, 2024 | Friday | News
Oxford Medical Products Announces Promising Topline Results from First RCT of Sirona Weight Loss Technology

 Oxford Medical Products is pleased to announce positive topline results from the first randomised controlled trial (RCT) of Sirona, its innova...

October 31, 2024 | Thursday | News
MSD and Moderna Launch Pivotal Phase 3 Trial for V940 in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the initiation of INTerpath-009, a piv...

October 29, 2024 | Tuesday | News
Jubilant Therapeutics Advances Innovative Cancer Therapies with First Patient Dosing in Global Trials for JBI-802 and JBI-778

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...

October 28, 2024 | Monday | News
Orexo Begins Dosing for Intranasal Epinephrine Study in Allergy Patients, Aiming to Advance OX640 Toward Regulatory Approval

OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...

October 28, 2024 | Monday | News
Adona Medical Achieves Milestone with First-in-Human Use of Novel Interatrial Shunt for Heart Failure

Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced the successful first-in-human use of ...

October 28, 2024 | Monday | News
Two Australian Scientists Awarded CSL Centenary Fellowships to Advance Cancer Research

 Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. The Fellowships were presented ...

October 25, 2024 | Friday | News
AbbVie and Gedeon Richter Forge New Agreement to Explore Treatments for Neuropsychiatric Disorders

 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...

October 25, 2024 | Friday | News
GSK Announces Promising Data for Arexvy Vaccine in Younger Adults at Risk for RSV

GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...

October 25, 2024 | Friday | News
PolTREG’s Early Treatment with PTG-007 Could Offer Functional Cure for Children at Risk of Type 1 Diabetes

Treating diabetes patients earlier with PTG-007 could provide functional cure Recruitment will go ahead after European Medicines Agency approval Comp...

October 24, 2024 | Thursday | News
Eli Lilly’s Donanemab Receives MHRA Approval for Alzheimer's Treatment in Great Britain

Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...

October 24, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close